Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, ...

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder associated with liver disease, ranging from fibrosis to ...

Researchers have outlined a new bronchoalveolar lavage (BAL) protocol to improve the reliability of reports on the biochemical efficacy of treatments for alpha-1 antitrypsin deficiency (AATD). The ...

Alvelestat is another candidate in its pipeline, which is being developed for the treatment of patients with alpha-1 antitrypsin deficiency-associated lung disease [AATD-LD]. However, the company ...

Background Bronchoalveolar lavage (BAL) is essential in determining the efficacy of novel therapies in alpha-1 antitrypsin deficiency (AATD). These require initial proof-of-concept demonstration that ...

Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD).

The transition to patient dosing and anticipated data readouts in the second half of 2025 are expected to strengthen Korro Bio’s position in treating alpha-1 antitrypsin deficiency (AATD ...

At a recent support group meeting for alpha-1 antitrypsin deficiency (AATD) patients, someone asked me a question I wasn’t expecting. He asked if I thought coffee was good for AATD patients. I did a ...

The following is a summary of “Higher healthcare cost and utilization before and after diagnosis of AATD in the United States,” published in the November 2024 issue of Pulmonology by Blanchette et al.

Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease that affects approximately 70,000 patients in the United States. The analyst from ...

该公司强调，这家生物科技公司专注于RNA编辑是其积极展望的重要因素。 Korro Bio的主要项目KRRO-110针对的是α-1抗胰蛋白酶缺乏症（AATD），这是一种罕见的肺部疾病，在美国约有70,000名患者受到影响。 Jones Trading的分析师对Korro Bio技术的潜力表示信心，特别是使用 ...